Photoswitchable distance constraints in the form of photoisomerizable chemical cross-links offer a general approach to the design of reversibly photocontrolled proteins. To apply these effectively, however, one must have guidelines for the choice of cross-linker structure and cross-linker attachment sites. Here we investigate the effects of varying cross-linker structure on the photocontrol of folding of the Fyn SH3 domain, a well-studied model protein. We develop a theoretical framework based on an explicit-chain model of protein folding, modified to include detailed model linkers, that allows prediction of the effect of a given linker on the free energy of folding of a protein. Using this framework, we were able to quantitatively explain the experimental result that a longer, but somewhat flexible, cross-linker is less destabilizing to the folded state than a shorter more rigid cross-linker. The models also suggest how misfolded states may be generated by cross-linking, providing a rationale for altered dynamics seen in nuclear magnetic resonance analyses of these proteins. The theoretical framework is readily portable to any protein of known folded state structure and thus can be used to guide the design of photoswitchable proteins generally.

. Chloroquine a potent antimalarial also demonstrates potency against selected cancers. In this study, we demonstrate pulmonary delivery of encapsulated chloroquine phosphate (CQP) using three poly(glycerol adipate-co--pentadecalactone) microparticles, PGA-co-PDL, PEG1500-PGA-co-PDL and PEG4500-PGA-co-PDL, and its effects on lung cancer cell growth. Methods. Microparticles encapsulated with CQP were prepared using spray drying-double emulsion technique. Encapsulation efficiency, water content, density, morphology and in-vitro release (PBS, pH 7.4) was characterised. Furthermore, aerosolisation behaviour was performed using the next generation impactor at 60L/min via HandiHaler® containing 20mg powder in HPMC capsule (size 2). MTT assay quantified the effect of encapsulated CQP and carrier-free CQP on human lung cancer bronchial epithelial cell (NCI-H727) proliferation. Results: PGA-co-PDL (11.4KDa), PEG1500-PGA-co-PDL (12.4KDa) and PEG4500-PGA-co-PDL (13.6KDa) resulted in low encapsulation efficiency (13.11±1.23, 10.52±0.86, 9.25±1.02). Furthermore, a biphasic release profile was predominant for all formulations, with ~40-45% of payload released after 24h. The aerosolisation performance (%FPF) was significantly greater for PEG1500-PGA-co-PDL (13.05±0.46%) and PEG4500-PGA-co-PDL( 14.66±0.46%) compared to PGA-co-PDL (9.52±0.50%) microparticle carriers. The higher FPF achieved with PEG4500-PGA-co-PDL microparticles was due to the significantly lower water content and true density (0.76±0.12%, 0.98±0.07g/cm3) respectively, as opposed to PEG1500-PGA-co-PDL (1.04±0.25%, 1.17±0.12g/cm3) and PGA-co-PDL (1.73±0.84, 1.24±0.35g/cm3), indicating less aggregation and enhanced flow properties. Treatment, 240-0.25µM, using carrier-free CQP (61.71±9.25-9.78±2.59) and encapsulated CQP (PGA-co-PDL: 63.88±11.13-19.38±8.55, PEG1500-PGA-co-PDL: 56.73±9.41-26.75±13.58, PEG4500-PGA-co-PDL: 62.46±8.57-25.24±5.41) resulted in a decrease in cell viability. Conclusion: Results from this investigation indicate CQP encapsulated with in PGA-co-PDL and PEG-PGA-co-PDL microparticles show promise as a pulmonary delivery system for treatment of lung cancers.

Poly(glycerol adipate-co-o-pentadecalactone) (PGA-co-PDL) was previously evaluated for the colloidal delivery of a-chymotrypsin. In this article, the effect of varying polymer molecular weight (MW) and chemistry on particle size and morphology; encapsulation efficiency; in vitro release; and the biological activity of a-chymotrypsin (a-CH) and lysozyme (LS) were investigated. Microparticles were prepared using emulsion solvent evaporation and evaluated by various methods. Altering the MW or monomer ratio of PGA-co-PDL did not significantly affect the encapsulation efficiency and overall poly(1,3-propanediol adipate-co-o-pentadeca- lactone) (PPA-co-PDL) demonstrated the highest encapsulation efficiency. In vitro release varied between polymers, and the burst release for a-CH-loaded microparticles was lower when a higher MW PGA-co-PDL or more hydrophobic PPA-co-PDL was used. The results suggest that, although these co-polyesters could be useful for protein delivery, little difference was observed between the different PGA-co-PDL polymers and PPA-co-PDL generally provided a higher encapsulation and slower release of enzyme than the other polymers tested.

Poly(glycerol adipate-co-o-pentadecalactone) (PGA-co-PDL) was previously evaluated for the colloidal delivery of a-chymotrypsin. In this article, the effect of varying polymer molecular weight (MW) and chemistry on particle size and morphology; encapsulation efficiency; in vitro release; and the biological activity of a-chymotrypsin (a-CH) and lysozyme (LS) were investigated. Microparticles were prepared using emulsion solvent evaporation and evaluated by various methods. Altering the MW or monomer ratio of PGA-co-PDL did not significantly affect the encapsulation efficiency and overall poly(1,3-propanediol adipate-co-o-pentadeca- lactone) (PPA-co-PDL) demonstrated the highest encapsulation efficiency. In vitro release varied between polymers, and the burst release for a-CH-loaded microparticles was lower when a higher MW PGA-co-PDL or more hydrophobic PPA-co-PDL was used. The results suggest that, although these co-polyesters could be useful for protein delivery, little difference was observed between the different PGA-co-PDL polymers and PPA-co-PDL generally provided a higher encapsulation and slower release of enzyme than the other polymers tested.

Poly(glycerol adipate-co-o-pentadecalactone) (PGA-co-PDL) was previously evaluated for the colloidal delivery of a-chymotrypsin. In this article, the effect of varying polymer molecular weight (MW) and chemistry on particle size and morphology; encapsulation efficiency; in vitro release; and the biological activity of a-chymotrypsin (a-CH) and lysozyme (LS) were investigated. Microparticles were prepared using emulsion solvent evaporation and evaluated by various methods. Altering the MW or monomer ratio of PGA-co-PDL did not significantly affect the encapsulation efficiency and overall poly(1,3-propanediol adipate-co-o-pentadeca- lactone) (PPA-co-PDL) demonstrated the highest encapsulation efficiency. In vitro release varied between polymers, and the burst release for a-CH-loaded microparticles was lower when a higher MW PGA-co-PDL or more hydrophobic PPA-co-PDL was used. The results suggest that, although these co-polyesters could be useful for protein delivery, little difference was observed between the different PGA-co-PDL polymers and PPA-co-PDL generally provided a higher encapsulation and slower release of enzyme than the other polymers tested.

Poly(glycerol adipate-co-o-pentadecalactone) (PGA-co-PDL) was previously evaluated for the colloidal delivery of a-chymotrypsin. In this article, the effect of varying polymer molecular weight (MW) and chemistry on particle size and morphology; encapsulation efficiency; in vitro release; and the biological activity of a-chymotrypsin (a-CH) and lysozyme (LS) were investigated. Microparticles were prepared using emulsion solvent evaporation and evaluated by various methods. Altering the MW or monomer ratio of PGA-co-PDL did not significantly affect the encapsulation efficiency and overall poly(1,3-propanediol adipate-co-o-pentadeca- lactone) (PPA-co-PDL) demonstrated the highest encapsulation efficiency. In vitro release varied between polymers, and the burst release for a-CH-loaded microparticles was lower when a higher MW PGA-co-PDL or more hydrophobic PPA-co-PDL was used. The results suggest that, although these co-polyesters could be useful for protein delivery, little difference was observed between the different PGA-co-PDL polymers and PPA-co-PDL generally provided a higher encapsulation and slower release of enzyme than the other polymers tested.

Diclofenac sodium (DCS), a non-steroidal anti-inflammatory drug used for posttraumatic pain and rheumatoid arthritis, has bitter taste. Thus formulating orally dissolving tablet containing taste-masked microspheres of diclofenac sodium is extremely advantageous and challenge.

Diclofenac sodium (DCS), a non-steroidal anti-inflammatory drug used for posttraumatic pain and rheumatoid arthritis, has bitter taste. Thus formulating orally dissolving tablet containing taste-masked microspheres of diclofenac sodium is extremely advantageous and challenge.

Diclofenac sodium (DCS), a non-steroidal anti-inflammatory drug used for posttraumatic pain and rheumatoid arthritis, has bitter taste. Thus formulating orally dissolving tablet containing taste-masked microspheres of diclofenac sodium is extremely advantageous and challenge.